Endo (NDOI) Retained Earnings : $-731 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Endo Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Endo's retained earnings for the quarter that ended in Dec. 2024 was $-731 Mil.

Endo's quarterly retained earnings declined from Apr. 2024 ($0 Mil) to Sep. 2024 ($-382 Mil) and declined from Sep. 2024 ($-382 Mil) to Dec. 2024 ($-731 Mil).

Endo's annual retained earnings declined from Dec. 2022 ($0 Mil) to Dec. 2023 ($-15,354 Mil) but then increased from Dec. 2023 ($-15,354 Mil) to Dec. 2024 ($-731 Mil).

Endo Retained Earnings Historical Data

The historical data trend for Endo's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Retained Earnings Chart

Endo Annual Data

Trend

Dec22

Dec23

Dec24

Retained Earnings

-15,354.43

-730.86

Endo Quarterly Data
	Jun23	Sep23	Dec23	Apr24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial			-	-15,354.43	-	-381.55	-730.86

Endo Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Endo (OTCPK:NDOI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Endo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.endo.com

Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.